Jinming Zhou | Medicinal Chemistry | Best Researcher Award Posted on 09/11/202409/11/2024 by sciencefatherLeave a Comment on Jinming Zhou | Medicinal Chemistry | Best Researcher Award Dr. Jinming Zhou | Medicinal Chemistry| Best Researcher Award Research and Grant Success: Dr. Zhou’s research has been consistently supported by prestigious National Natural Science Foundation (NCSF) grants, with four approvals to date. This grant success not only reflects the high quality and impact of his research but also indicates his capacity to conduct rigorous and relevant studies that address critical health challenges. Dr. Jinming Zhou, Zhejiang Normal University , China Profile Scopus OrcID 🌱EARLY ACADEMIC PURSUITS Dr. Zhou’s academic journey began at Beijing Normal University, where he earned his Bachelor of Science (B.S.) in 2000 and Master of Science (M.S.) in 2003. His passion for rational drug design led him to pursue a Ph.D. at the Shanghai Institute of Organic Chemistry, where he specialized in this field, establishing a strong foundation in medicinal chemistry. Postdoctoral training followed at McGill University in Canada, where he continued advancing in rational drug design and gained international research exposure. 💼 PROFESSIONAL ENDEAVORS In 2010, Dr. Zhou joined the Institute of Medicinal Biotechnology at the Chinese Academy of Medical Science as an Associate Professor. Demonstrating outstanding contributions in drug research, he achieved full professorship in 2017. His career took a new turn in 2018 when he accepted a professorship at Zhejiang Normal University, where he also became the Director of the Drug Development and Innovation Center. Dr. Zhou’s leadership at this center has been pivotal in establishing innovative practices and groundbreaking projects. 🔬CONTRIBUTIONS AND RESEARCH FOCUS Dr. Zhou’s research team is at the forefront of developing anti-viral and anti-cancer drugs. His group combines rational drug design and applied medicinal research to create effective therapeutic solutions. His work has a special emphasis on translational medicine, aiming to bridge scientific research and clinical applications. He has secured four prestigious National Natural Science Foundation (NCSF) grants, supporting his work in advancing therapeutic drug development. 📚ACADEMIC CITES With over a hundred publications, Dr. Zhou has significantly impacted medicinal chemistry, particularly in antiviral and anticancer drug design. His research has become a widely cited reference in related studies, underscoring his scientific contributions’ value and relevance. 🌍IMPACT AND INFLUENCE Dr. Zhou’s influence in the medicinal chemistry field is highlighted by his 100+ publications in high-impact journals, showcasing the scientific community’s recognition of his expertise. His achievements were honored in 2012 with the prestigious “Xiehe Star” award, recognizing his exceptional contributions to the field of drug design. 🌟LEGACY AND FUTURE AND CONTRIBUTIONS As Dr. Zhou continues his work at the Drug Development and Innovation Center, he is shaping a new generation of researchers focused on tackling global health challenges. His legacy is built not only on his published works but also on his mentorship and role in expanding the field of drug innovation. His ongoing research promises to further the understanding of rational drug design and its applications in combating complex diseases. 📄Publications “Inducing or enhancing protein-protein interaction to develop drugs: Molecular glues with various biological activity” Authors: Zhang, R., Zheng, Y., Xiang, F., Zhou, J. Journal: European Journal of Medicinal Chemistry, 2024, 277, 116756 “METTL3 inhibitor suppresses the progression of prostate cancer via IGFBP3/AKT pathway and synergizes with PARP inhibitor” Authors: Chen, X., Wang, M., Wang, H., Zhou, J., Wu, M. Journal: Biomedicine and Pharmacotherapy, 2024, 179, 117366 “Autophagy mediated targeting degradation, a promising strategy in drug development” Authors: Zhang, J., Pan, X., Ji, W., Zhou, J. Journal: Bioorganic Chemistry, 2024, 149, 107466 “A novel hydrophobic tag leads to the efficient degradation of programmed death-ligand 1” Authors: Gao, J., Xie, Y., Zhang, J., Cen, S., Zhou, J. Journal: RSC Medicinal Chemistry, 2024, 15(9), pp. 3038–3047 “Design and Synthesis of Dual-Target Inhibitors Targeting Androgen Receptors and Glucocorticoid Receptors to Overcome Antiandrogen Resistance in Castration-Resistant Prostate Cancer” Authors: Li, C., Han, X., Yan, Q., Wu, M., Zhou, J. Journal: Journal of Medicinal Chemistry, 2024, 67(5), pp. 3419–3436